TiGenix And Lonza Partner For Complex Perianal Fistulas In Crohn’s Disease Treatment

TiGenix And Lonza Partner For  Complex Perianal Fistulas In Crohn’s Disease Treatment
TiGenixTiGenix, an advanced biotechnological company committed to developing and marketing new therapeutics from allogeneic expanded adipose-derived stem cells (eASCs) for autoimmune and inflammatory diseases, together with Lonza, a leading and global company of biological and cell therapy manufacturing, have recently announced an agreement for Cx601, TiGenix's eASC product, to address Crohn's disease. The new agreement stipulates that Lonza will manufacture material for the Cx601 Phase 3 trial in the US, to be conducted at Lonza's cell therapy production facility in Walkersville, Maryland (US). Cx601 is a locally-injected suspension of allogeneic expanded adipose-derived stem cells (eASCs) appropriated to treat complex perianal fistulas in patients suffering with Crohn's disease; the drug is currently in ongoing Phase 3 studies in Europe. Since TiGenix received positive feedback from the US Food and Drug Administration (FDA) at a recent meeting, the company is advancing Cx601'
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *